Prediction of ftorafur disposition in rats and man by a physiologically based pharmacokinetic model

Sakiya, Yoko; Tsuemura, Yoshiji; Sawada, Yasufumi; Hanano, Manabu; Marunaka, Teruyoshi; Umeno, Yukihiko

doi:10.1016/0378-5173(85)90174-7

Cited by 7 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The decrease in sensitivity obtained in serum can be reasonably attributed to the plasma proteins, such as albumin, bilirubin or hemoglobin, which can bind and interact with drug molecules, reducing the free drug concentration at the electrode surface, as already reported [ 60 , 61 ]. In case of ftorafur for example, it was reported that it weakly binds only to plasma protein (about 22%) [ 62 ], while etoposide is one of the few anti-cancer drugs that strongly binds (>90%) to plasma proteins [ 63 ]. Cyclophosphamide and ifosfamide exhibit relatively low protein binding.…”

Section: Resultsmentioning

confidence: 99%

Electrochemical Detection of Anti-Breast-Cancer Agents in Human Serum by Cytochrome P450-Coated Carbon Nanotubes

Baj-Rossi

Micheli

Carrara

2012

Sensors

View full text Add to dashboard Cite

We report on the electrochemical detection of anti-cancer drugs in human serum with sensitivity values in the range of 8–925 nA/μM. Multi-walled carbon nanotubes were functionalized with three different cytochrome P450 isoforms (CYP1A2, CYP2B6, and CYP3A4). A model used to effectively describe the cytochrome P450 deposition onto carbon nanotubes was confirmed by Monte Carlo simulations. Voltammetric measurements were performed in phosphate buffer saline (PBS) as well as in human serum, giving well-defined current responses upon addition of increasing concentrations of anti-cancer drugs. The results assert the capability to measure concentration of drugs in the pharmacological ranges in human serum. Another important result is the possibility to detect pairs of drugs present in the same sample, which is highly required in case of therapies with high side-effects risk and in anti-cancer pharmacological treatments based on mixtures of different drugs. Our technology holds potentials for inexpensive multi-panel drug-monitoring in personalized therapy.

show abstract

Section: Resultsmentioning

confidence: 99%